Avsnitt
-
Good Clinical has teamed up with Te Titoki Mataora, the MedTech Research Translator, to bring you the Te Titoki Mataora Podcast Series.
In this episode I chat with two Senior Research Fellows within The University of Auckland, Dr Haruna Suzuki-Kerr from the Faculty of Medical & Health Sciences, and Dr Julie Choisne, from Auckland Bioengineering Institute.
Dr Julie Choisne's research is in the realm of paediatric biomechanics, looking at how children grow, how their bones grow, and how muscle growth affects their movements and applying that knowledge to children that have bone deformities.
Dr Haruna Suzuki-Kerr's research involves trying to develop a new technology that can help treat individuals with sensory neural hearing loss.
The episode particularly focuses on the Future Leaders module and other associated modules under the health tech capability programme provided by Te Tītoki Mataora, which are a part of an initiative aimed at supporting emerging researchers, entrepreneurs, clinicians, and others alike into the MedTech fields. Julie and Haruna are both actively involved in the programme, and they share insights into the modules provided by Te Titoki Mataora and their experiences. We also discuss other topics such as the importance of MedTech and innovation in New Zealand and envisioning NZ's future in this space.
Check out more about Te Titoki Mataora here: https://www.cmdt.org.nz/
Podcast Takeaways:
Early-career researchers face numerous challenges, including managing their first research projects, writing grants, and balancing personal and professional life. The health tech capability programme aims to support them through this transition.Beyond technical expertise, researchers need to develop soft skills, such as effective communication, networking, and collaboration, to advance their careers and succeed in grant writing and commercialisation.Learning from experienced professionals and forming networks with peers at similar career stages is crucial for growth and overcoming common challenges in the MedTech field.Researchers often focus too heavily on the technical side of their work and forget to highlight the broader impact. Programmes offered through Te Titoki Mataora help researchers clarify the long-term significance and user needs of their projects.New Zealand is becoming a hub for MedTech innovation, with successful biotech and health tech companies emerging. The Future Leaders module aims to foster this growth and help researchers contribute to this vibrant ecosystem.
Timestamps:
00:00 Introduction
03:09 Insights on New Zealand's MedTech Ecosystem
05:51 Challenges in Technology Development
09:12 The Importance of Collaboration in Health Tech
12:00 Overview of the Future Leaders Module
14:50 Supporting Emerging Researchers
18:10 Skills Development for Future Leaders
20:53 Networking and Collaboration Opportunities
24:03 Vision for the Future of MedTech in New Zealand
𝐊𝐄𝐘𝐖𝐎𝐑𝐃𝐒:- MedTech, Future Leaders, New Zealand, Health Tech, Pediatric Care, Collaboration, Research, Innovation, Technology Development, Emerging Researchers -
Good Clinical has teamed up with Te Titoki Mataora, the MedTech Research Translator, to bring you the Te Titoki Mataora Podcast Series. In this episode, meet Dr Caz Hales, a registered nurse and academic working in the research field of obesity care within health systems, based at Victoria University of Wellington. Her research focuses on reshaping the approach to healthcare for people living with obesity by advocating for a shift from the stigmas surrounding obesity to creating equitible, safe, and accessible care environments.
A key area of her recent research includes a new project venture with the help of Te Titoki Mataora, which involves the use of virtual reality (VR) technology as a training platform to create innovative educational tools for healthcare professionals, helping them better understand and care for people living with obesity.
You can find out more about Dr Caz Hales here:
Dr Caz Hales - LinkedIn
Podcast Takeaways:
Caz emphasises the need to shift healthcare practices from removing the stigmatisation around obesity to creating environments that provide equitable, safe, and inclusive care for people living with obesity (PlwO).Caz’s research is rooted in collaboration with PlwO, their whānau/families, and communities to ensure that their voices and needs are at the centre of developing healthcare services.Caz is exploring innovative approaches, such as using a virtual reality (VR) education platform as a training tool to educate healthcare professionals on how to provide better care for PlwO, focusing on empathy, cultural safety, equipment use, and patient movement safety.Caz advocates for a human-centred approach to healthcare, ensuring that all patients, regardless of body size, have access to respectful, dignified care, including appropriate equipment and support.Timestamps:
00:00 Introduction to Dr Caz Hales and her Nursing Background06:48 Pivoting into Academia07:53 Current Research Focusing on PlwO 11:05 Inequities in Healthcare Services for PlwO16:01 Importance of Use of Language and Frameworks22:06 Clinically Defining Obesity28:00 Downstream Impacts of a Lack of Equitable Environments for PlwO35:45 Caz's Project Supported by Te Titoki Mataora45:00 Future Directions in Research and Care -
Saknas det avsnitt?
-
Good Clinical has teamed up with Te Titoki Mataora, the MedTech Research Translator, to bring you the Te Titoki Mataora Podcast Series.
In this episode, meet Dr Gavin Harris, Anatomical Pathologist from Canterbury Health Laboratories, who discusses the development of a diagnostic assessment tool using machine-learning algorithms to assess breast cancer aggressiveness and recurrence risk.
We chat about several topics such as the process of training the algorithm on clinical data, the challenges of validation, and the regulatory steps required for commercialisation. He emphasises the importance of multidisciplinary collaboration, networks, and funding support from entities like Te Titoki Mataora, and shares his experience navigating the complexities of both the healthcare and commercial sectors. The ultimate goal is to provide a personalised tool that can improve clinical decision-making and patient outcomes by accurately assessing cancer recurrence risk and other components with over 95% accuracy.
Podcast Takeaways:
Gavin is developing an AI tool to improve breast cancer risk assessment by identifying tumours with aggressive biological signatures that might not be evident through traditional diagnostics, as well as the likelihood of tumour recurrence.His tool has the potential to identify genomic features of the tumour that would otherwise only be identified through expensive molecular testing that not everyone can currently access. Having such a novel tool available means increased access, lower cost, and reduced time required for diagnostics and assessment.The current accuracy of the tool is around 80%, but the team is aiming for a higher threshold preferably above 95%, to be confident in its diagnostic value.Gavin highlights the importance of multidisciplinary collaboration such as with specialists from oncology, pathology, and AI, as well as the support of entities like Te Titoki Mataora and Health New Zealand.The project has to meet several parameters related to FDA and TGA regulations, with a pathway to commercialisation taking 3-5 years, involving rigorous testing and validation on independent and international datasets.Gavin underscores how crucial research offices, innovation hubs, and funding bodies are in providing the necessary infrastructure and resources for such complex projects.Gavin reflects on how much he has learned in transitioning from clinical work to understanding the complexities of commercialisation, regulation, and scalability, emphasising the value of building strong networks and continuously learning.
Timestamps:
00:00 Introduction and Background03:07 Gavin Harris's Journey in Pathology05:53 Traditional Approaches to Breast Cancer Diagnosis11:00 Incorporating Algorithmic Approaches19:06 Funding and Project Support25:40 Research Collaborations30:00 Commercialisation and Regulatory Challenges41:15 The Support of Te Titoki Mataora47:35 Advice for Innovators in Healthcare _ -
Good Clinical has teamed up with Te Titoki Mataora, the MedTech Research Translator, to bring you the Te Titoki Mataora Podcast Series.
In this latest episode, meet Prof. Maggie Huckabee, Founding Director and Chief Scientific Officer, and Emma Hayes, Chief Executive Officer, at Swaltech.
Swaltech is a medical device company that have developed innovative assessment tools that clinicians can incorporate into treatment planning and rehabilitation for individuals with dysphagia. Swaltech have developed an app called BiSSkapp (Biofeedback in Strength and Skill Training) that works alongside a surface electromyography (sEMG) device to detect and display muscle activity using sensors under the chin. This allows dysphagia rehabilitation to be achieved in the individual's own home with remote clinician supervision.
You can find out more about Swaltech here: https://swaltech.com/
Episode Takeaways:
Swaltech have developed an innovative, non-invasive solution for remote dysphagia rehabilitation, combining their BiSSkapp with a biofeedback device.Their solution works by placing electrodes under the chin, which connects to a tablet to provide muscle feedback, allowing for at-home use with clinician-prescribed settings.The adaptive biofeedback can adjust difficulty to patient progress, and personalised voice prompts from clinicians can be incorporated to help with progress and motivation.There are ongoing clinical trials at University of Canterbury and University of Florida. - Swaltech's aim is providing state-of-the-art dysphagia management, with future plans for paediatrics expansion and new product iterations.Chapters:
00:00 Introduction to Dysphagia and Swaltech
03:09 Understanding Dysphagia: Prevalence and Impact
06:02 Clinical Interventions for Dysphagia
08:55 Innovative Approaches to Swallowing Rehabilitation
11:46 The Birth of Swaltech and Its Mission
15:09 The BiSSkapp: Biofeedback in Strength and Skill Training
18:05 Patient-Centric Design and Usability
24:20 Commercialisation and Regulatory Strategy
31:00 Future Aspirations for Swaltech
𝐊𝐄𝐘𝐖𝐎𝐑𝐃𝐒:- Dysphagia, Swaltech, MedTech, swallowing disorders, rehabilitation, biofeedback, clinical interventions, Parkinson's disease, stroke, paediatric dysphagia
#goodclinical #goodclinicalpodcast #goodclinicalexplains #goodclinicalevents #goodclinicalnetwork #innovation #podcast #newzealand #commercialization #venturecapital #vc #clinicalresearchassociate #technologytransfer #biotech #science #choices #country #entrepreneur #products #clinicalresearch #biotech #clinicalpractice #healthcare #clinicaltrials #medicine #humanhealthanddiseases #medtech #dysphagia -
Good Clinical has teamed up with Te Titoki Mataora, the MedTech Research Translator, to bring you the Te Titoki Mataora Podcast Series.
In this episode, meet Dr. Yaara Yarmut, the Chief Regulatory Officer at Alimetry, a medical device company who have developed an innovative gastric monitoring device that performs body surface gastric mapping using an electrode array.
Yaara discusses her journey from veterinary medicine to MedTech and how they differ, where Alimetry is currently at as a late-stage startup, and the regulatory challenges that may be faced by MedTech startups. Yaara also emphasises the importance of having a strong regulatory framework, the important role of advisory boards in supporting and fostering innovation, and the need for more funding and talent acquisition in New Zealand's MedTech industry scene.
You can find out more about Alimetry here:
https://www.alimetry.com/
Podcast Takeaways:
Yaara transitioned from veterinary medicine to MedTech due to a desire for innovation.Alimetry's gastric monitoring technology aims to simplify diagnosis for gastric disorders.Regulatory challenges can be significant for MedTech startups, especially in New Zealand.A strong regulatory framework is key and can enable innovation rather than hinder it.Advisory boards play a crucial role in guiding early-stage MedTech projects.Funding and talent acquisition are critical for the growth of the MedTech ecosystem.Learning from mistakes is essential in the MedTech industry.New Zealand's small market can pose challenges for MedTech companies seeking growth.
Chapters:
00:00 Introduction to MedTech Innovation
03:04 From Veterinary Medicine to MedTech Leadership
05:56 Alimetry's Gastric Monitoring Technology
08:45 Navigating Regulatory Challenges in MedTech
12:04 The Role of Advisory Boards in Innovation
14:55 Building a Supportive Ecosystem for Startups
18:10 The Importance of a Strong Regulatory Framework
28:00 Yaara's Perspective on how to Invigorate NZ MedTech
𝐑𝐄𝐋𝐀𝐓𝐄𝐃 𝐊𝐄𝐘𝐖𝐎𝐑𝐃𝐒:- MedTech, innovation, regulatory framework, startup ecosystem, gastric monitoring, advisory boards, funding, veterinary medicine, clinical trials, New Zealand #goodclinical #goodclinicalpodcast #goodclinicalexplains #goodclinicalevents #goodclinicalnetwork #innovation #podcast #newzealand #commercialization #venturecapital #vc #clinicalresearchassociate #technologytransfer #biotech #science #choices #country #entrepreneur #products #clinicalresearch #biotech #clinicalpractice #healthcare #clinicaltrials #medicine #humanhealthanddiseases #gastricdisorders #medtech #Alimetry -
Good Clinical has teamed up with Te Titoki Mataora, the MedTech Research Translator, to bring you the Te Titoki Mataora Podcast Series.
In this episode, Dr. Grace Walker, Co-founder and Chief Regulatory Officer at Tautoko Technology discusses her work in developing a patch insulin pump with wraparound support and education software to improve diabetes management.
One of Tautoko Technology's main goals is ensuring their device is accessible to all, so that it gets into the hands of those that need it most.
You can find out more about Dr. Grace Walker and Tautoko Technology here: https://www.linkedin.com/in/gracewalkernz/
Tautoko Technology - LinkedIn
Dr Grace Walker - LinkedIn
Podcast Takeaways:
Tautoko Tech is developing a patch insulin pump with support software to improve diabetes management.The company aims to make the device more accessible by offering the pump for free and charging for the consumables.Rural communities face challenges in accessing healthcare, and Tautoko Tech's solution aims to bridge the gap.The team is driven by the desire to make a difference and improve the lives of people with diabetes.Tautoko Techs plans to raise the funds required to bring their MVP to market.They are working on getting regulatory pre-submission ready and filing a patent for their next version, and then will proceed with hotel trials and clinical trials.Chapters:
00:00 Introducing Grace Walker and Tautoko Technology
01:05 The Problem Tautoko Tech is Solving
03:50 Dr. Grace Walker's Journey and Passion
06:58 The Impact of Diabetes on Rural Communities
13:15 Making Diabetes Care More Accessible
18:45 Discussing the Tautoko Tech Team
20:17 Current Project and Future Plans
22:08 Navigating the Regulatory Pathway
26:50 Considering Biocompatibility and User Experience
29:03 Accuracy and Claims
34:58 Plans for Pitching and Funding
39:10 Advice to Aspiring Entrepreneurs -
Good Clinical has teamed up with Te Titoki Mataora, the MedTech Research Translator, to bring you the Te Titoki Mataora Podcast Series.
In this episode, Professor Grant Searchfield, Head of Audiology at The University of Auckland and Founder and Scientific Director of TrueSilence Therapeutics, discusses the development of a non-invasive polytherapeutic method for the treatment of Tinnitus. The method combines sound therapy, perceptual training, and psychological interventions alongside the support of machine learning to provide a personalised multifaceted approach to helping individuals with Tinnitus.
You can find out more about Prof Searchfield and TrueSilence Therapeutics here: Professor Grant Searchfield - LinkedIn
True Silence Therapeutics
Podcast Takeaways:
Tinnitus is a common complaint affecting millions of people worldwide.2. Current treatments for tinnitus have been limited in their effectiveness.3. Tinnitus is a network problem, involving multiple parts of the auditory system and brain.4. Personalised and tailored treatments are important for addressing individual differences in tinnitus.5. The use of biosensors and artificial intelligence shows promise in optimising treatment outcomes.Chapters:
00:00 Introduction and Background
03:12 Understanding Tinnitus as a Network Problem
05:04 Exploring Treatment Approaches for Tinnitus
09:43 The Importance of Personalized and Tailored Treatments for Tinnitus
13:33 The Potential of Biosensors and Artificial Intelligence in Tinnitus Treatment
𝐑𝐄𝐋𝐀𝐓𝐄𝐃 𝐊𝐄𝐘𝐖𝐎𝐑𝐃𝐒:
tinnitus, treatment, non-invasive, auditory system, brain, sound therapy, perceptual training, psychological interventions, personalised treatment, biosensors, artificial intelligence
#goodclinical #goodclinicalpodcast #goodclinicalexplains #goodclinicalevents #goodclinicalnetwork #innovation #podcast #newzealand #commercialization #venturecapital #vc #clinicalresearchassociate #technologytransfer #biotech #science #choices #country #entrepreneur #products #clinicalresearch #biotech #clinicalpractice #healthcare #clinicaltrials #medicine #humanhealthanddiseases Please share with your friends and family. Also don't forget to like, subscribe, and hit the notification bell to notify you if I post a new video. Much love and God bless -
Good Clinical has teamed up with Te Titoki Mataora, the MedTech Research Translator, to bring you the Te Titoki Mataora Podcast Series.
In this epsiode, Dr. Xuxu Amoozegar-Montero, founder of Uuna, discusses the problems with traditional bras and the innovative solution her company is developing. Uuna uses 3D scanning and knitting technology to create custom-fit bras that address issues of comfort, sizing inconsistency, and sustainability. The company is initially targeting the post-surgery market and plans to expand to a general market in the future.
Dr. Amoozegar-Montero emphasizes the importance of understanding and working with the end user, networking, and perseverance in entrepreneurship.
Podcast Takeaways:
Traditional bras have numerous problems, including discomfort, inconsistent sizing, and unsustainable manufacturing.Uuna Studio uses 3D scanning and knitting technology to create custom-fit bras that address these issues.The company is initially targeting the post-surgery market and plans to expand to a general market in the future.Understanding and working with the end user, networking, and perseverance are key in entrepreneurship.Timestamps:
00:00 Introduction
03:00 Introducing Oona Studio
06:00 The Inspiration for Custom-Fit Bras
09:00 The Solution: 3D Scanning and Knitting
12:00 Targeting the Post-Surgery Market
14:30 The Role of KiwiNet and Te Tukimata Ora
19:00 Expanding Skillset and Thinking Long-Term
23:00 The Future of Oona Studio
30:00 Advice for Entrepreneurs
33:00 Where to Find More Information
Keywords
bras, 3D scanning, 3D knitting, custom-fit, sizing, comfort, sustainability, post-surgery market, general market, networking, perseverance -
Good Clinical has teamed up with Te Titoki Mataora, the MedTech Research Translator, to bring you the Te Titoki Mataora Podcast Series.
In this epsiode, Dr. Vickie Shim, a Senior Research Fellow at the Auckland Bioengineering Institute, discusses her work in neuromechanics and its application to injury and degenerative diseases, specifically mild traumatic brain injury (TBI). She explains that neuromechanics focuses on how brain tissue responds to external mechanical stimuli, such as impacts, and the potential damage that can occur.
Dr. Shim's research involves studying the brains of high school rugby players throughout a season to track brain changes and correlate them with head impacts. The goal is to develop an AI-based tool that can predict recovery trajectories and inform personalized treatment plans for individuals with TBI.
Podcast Takeaways:
Neuromechanics focuses on how brain tissue responds to external mechanical stimuli, such as impacts.Mild traumatic brain injury (TBI) is a common form of TBI, with about 80% of all TBIs falling into the mild range.Repetitive head impacts, such as those experienced in contact sports or by combat soldiers, can lead to long-term brain degenerative changes and increased risk of neurodegenerative diseases.Dr. Shim's research involves studying the brains of high school rugby players to track brain changes over a season and correlate them with head impacts.The goal is to develop an AI-based tool that can predict recovery trajectories and inform personalized treatment plans for individuals with TBI.
Timestamps:
00:00 Introduction to Neuromechanics and Dr. Vickie Shim's Research
01:22 Understanding Brain Tissue Response to Mechanical Impact
06:22 The Prevalence and Impact of Mild Traumatic Brain Injury
10:06 Tracking Brain Changes in High School Rugby Players
19:04 Developing an AI-Based Tool for Predicting Recovery Trajectories 2
6:40 Personalized Treatment Plans for Mild Traumatic Brain Injury -
Today’s guest is Dr Maddie White, Translational Scientist and Strategic Partnerships Manager at the Gillies McIndoe Research Institute in Wellington, New Zealand.
This episode is brought to you by SAPRO Consulting.
Dr. Maddie White, a translational scientist and strategic partnerships manager at Gillies-McIndoe Institute, discusses the role of translational scientists in moving research from the lab to real-world impact. She emphasizes the importance of translating academic ideas into commercially viable products or services.
Dr. White shares her personal journey into translational science and highlights the need for more awareness and education about career opportunities in this field. She also discusses a specific project she is involved in, developing a topical cream for the treatment of vascular birthmarks in infants.
Dr. White emphasizes the need for talent, infrastructure, and funding to drive the success of translational science in New Zealand.
You can find out more about Dr White and The Gillies McIndoe Research Institute here:
LinkedIn - Maddie White
Website - Gillies McIndoe Research Institute
Podcast Takeaways:
Academic ideas need to be translated into commercially viable products or services to have a meaningful impact.A "translational scientist" is someone who takes scientific ideas from the lab and translates them into real-world products or services.Translational scientists play a crucial role in moving research from the lab to real-world impact.There is a need for more awareness and education about career opportunities in translational science.Talent, infrastructure, and funding are essential for the success of translational science. Partnerships between academia and industry are key in driving the translation of research into practical applications.
Chapters
00:00 Introduction to Translational Science
01:00 Translating Academic Ideas into Real-World Impact
08:04 Overcoming Stigma and Misconceptions
13:18 The Importance of Money in Translational Science
19:49 Creating Collaborative Networks for Impactful Research
23:58 Developing a Topical Cream for Vascular Birthmarks
26:21 Partnerships for Bringing Research to Market
Keywords:
Translational science, research, lab, real-world impact, commercialization, academic, funding, talent, infrastructure, money, partnerships, topical cream, vascular birthmarks -
Good Clinical has teamed up with Te Titoki Mataora, the MedTech Research Translator, to bring you the Te Titoki Mataora Podcast Series.
Today’s guest is Dr Victor Dieriks, the Head of the Apha Synuclein Lab at the Centre for Brain Research at the University of Auckland. Dr Dieriks studies the role of alpha synuclein in the development of Parkinson's Disease and Multiple System Atrophy (MSA).
Parkinson’s disease (PD) is currently the fastest-growing chronic neurological disorder globally. An estimated 12 million people are living with PD, with around 12,000 of those residing in New Zealand.
Unfortunately, no treatments presently target the underlying mechanisms of PD, and clinical studies aimed at discovering disease-modifying medications are limited. This means that a truly effective, curative treatment remains years away. However, numerous interventions are available today that can significantly improve the quality of life for those with PD.
Dr Victor Dieriks has two active projects with Te Titoki Matora, MedTech Research Translator
Project #1: Developing a more New Zealand-centric approach to the management and treatment of Parkinson's disease. Dr Dieriks emphasizes the importance of actively involving patients and understanding their priorities, rather than solely relying on the perspectives of healthcare professionals and researchers.Patients1 with PD often express their desire for improved dignity and quality of life, rather than just a focus on a cure or restoring mobility.Project #2: involves the use of tears (eye fluid) as a potential biofluid source for detecting Parkinson's disease biomarkes. Tears are a relatively pure and stable biological fluid, making them a promising target for developing a non-invasive diagnostic test that can be easily obtained. A core aspect of this project is reducing the burden on the healthcare system, particularly the long wait times to see a neurologist for diagnosis. By developing a simple, tear-based test, patients can potentially bypass the need for more invasive procedures and receive earlier prognosis and treatment.Podcast Takeaways:
Parkinson's disease is not a single disease, but rather a collection of diseases with multiple causesThe normal function of alpha-synuclein is not fully understood, but it is known to play a role in neuronal communication and potentially in the gut and microbiomeCurrent treatments for Parkinson's, like levodopa and deep brain stimulation, only address the symptoms and cannot stop the underlying disease progressionA major challenge is that current therapies are tested too late, only after 70% of the relevant neurons have already died.Early detection is key, and recent breakthroughs have shown that alpha-synuclein clumps can be detected in spinal fluid or even potentially in less invasive samples like skin or nasal swabs, years before symptom onsetWhile genetic risk factors can be screened for, they only account for a small percentage of Parkinson's cases. Other risk factors include environmental exposures like metals, pesticides, and viral/bacterial infections that cause inflammationIn the absence of a cure, lifestyle interventions like exercise, healthy eating, and moderate coffee consumption can help delay the onset and progression of Parkinson's. Exercise, in particular, has been shown to have neuroprotective effects mediated by the hormone irisin.The gut-brain axis is also implicated in Parkinson's, with constipation and other gut symptoms often preceding the motor symptoms.Chapters
0:00 Introduction
01:10 "Parkinson's Disease" is a misnomer
02:50 Dieriks Lab Focus
06:00 Peculiarities of Neurodegenerative Diseases
09:00 Role of alpha synuclein
14:00 Treatment's available for Parkinson's Disease
19:00 Risk factors for Parkinson's Disease
24:00 Alternative sampling methods for determining risk of
PD 27:20 Interventions for slowing development
31:00 Coffee
32:12 Gut-brain Axis
35:25 New Zealand-centric approach to management and treatment of PD 39:00 Importance of having all stakeholders engaged
44:30 Tears can predict risk of Parkinson's Disease?
Keywords: Parkinson's Disease, TTM, Te Titoki Mataora, biomedical science, research, research translation, medtech, medical technologies, university research, intellectual property, commercialization.
Early Detection of Parkinson's Diseases | Dr Victor Dieriks | TTM Ep02 -
Today’s guest is Dr Haruna Suzuki-Kerr, Research Fellow at the University of Auckland in the Auditory & Vestibular Translational Neuroscience Cluster.
This episode is part of the Te Titoki Mataora Podcast Series, in collaboration with Te Titoki Mataora, the MedTech Research Translator.
Hearing loss is a common problem, in fact 1 in 6 people experience some form of hearing loss. Broadly speaking, hearing loss can be broken down into conductive hearing loss - think glue ear or damage to the ear drum - or sensorineural hearing loss (SNHL). SNHL is the most common type of hearing loss, and is caused by a pathology of the cochlea, auditory nerve, or central nervous system.
The problem - the inner ear apparatus is embedded deep within the skull, is very small, and thus is very difficult to study.
Enter Dr Haruna Suzuki-Kerr. Haruna and her team, with seed funding fro m Te Titoki Mataori, are developing a novel, non-invasive, light-based, medical technology and device for the investigation of the 1) structure and 2) chemistry of the inner ear.
To date Haruna and her team have assembled a multi-disciplinary team to inform the design of their medical device and increase the likelihood of commercial success. The initial proof of concept will be tested in sheep tissue, before moving into live sheep model, and then into man!
Chapters
00:00 Introduction and Background
02:00 The Different Types of Hearing Loss
04:50 Architecture of the Inner Ear
07:00 Studying Sensorineural Hearing Loss
11:00 Haruna's previous research experience and Holy Grail of this project
14:30 Inception of the Idea and Design
18:00 Why use light-based techniques?
22:30 Current Status of the Project
28:00 Commercialization Journey and TTM support
36:00 Next Steps for the Project and the ultimate goal
Keywords: hearing loss, sensorineural hearing loss, medical device, TTM, Te Titoki Mataora, biomedical science, research, research translation, medtech, medical technologies, university research, intellectual property, commercialization.
Using Light to Elucidate the Secrets of the Inner Ear | Dr Haruna Suzuki-Kerr | TTM Ep02 -
Good Clinical has teamed up with Te Titoki Mataora, the MedTech Research Translator, to bring you the Te Titoki Mataora Podcast Series.
Te Titoki Mataora (TTM) is a New Zealand-based organization focused on translating basic science into real outcomes in healthcare.
Here to provide an background to Te Titoki Mataora, the current framework to support research translation and some forward thinking perspectives is Distinguished Professor Sir Peter Hunter.
After identifying a need to translate basic science into real outcomes in healthcare Sir Peter Hunter and Di Siew founded the Consortium for Medical Device Technologies (CMDT). Over years this resulted in the spin out of a number of companies, as well as a bid for a MedTech Centre of Research Excellence (CoRE), and more recently Te Titoki Mataora, the MedTech Research Translator.
Te Titoki Mataora aims to develop a New Zealand-wide approach to medical technology translation by collaborating with universities, Callaghan Innovation, and the healthcare system. Supported by the Ministry of Business Innovation and Employment (MBIE) and the University of Auckland, the organization provides funding and support through programs like the Research Acceleration Program (RAP) to help researchers and spin-out companies progress from ideation to commercialization. TTM has already funded 69 projects and aims to create more high-paying jobs and successful medtech companies in New Zealand.
In Sir Peter's Words, "I don't see any reason why we can't be creating, over the next 10 years, another ten Fisher and Paykel Heathcares".
Keywords
Te Titoki Mataora, TTM, Consortium for Medical Device Technologies, CMDT, medical technology, translation, New Zealand, research acceleration program, RAP, spin-out companies, funding, high-paying jobs, medtech ecosystem
Sound Bites
"Te Taitoki Mataora is focused on translating basic science into real outcomes in healthcare."
"TTM aims to create more high-paying jobs and successful medtech companies in New Zealand."
"The Research Acceleration Program (RAP) provides funding and support for researchers and spin-out companies."
Chapters
00:00 Introduction and Background of Te Titoki Mataora (TTM)
03:46 Collaboration for Medical Technology Translation
09:06 The Research Acceleration Program (RAP)
12:15 Future Aspirations for TTM -
Today’s guest is Charlotte Bradshaw, the Founder & CEO of Evrima Technologies.
This episode is brought to you by SAPRO Consulting: https://www.saproconsulting.com.au/
Evrima aims to solve the problem of finding patients for clinical trials by building networks of clinicians and integrating trial information into their workflow. The goal is to make it easier for healthcare providers to identify eligible patients and provide them with trial options, with the ultimate vision is to have a measurable impact on the clinical trial value chain, enabling research to happen faster and getting treatments to the people who need them.
Evrima offers three products:
evripath, a referral network that connects sites, CROs, and sponsors to pharmacists and GPsevrilink, a recruitment platform that securely delivers participant referrals to sites, andevriquest, innovating recruitment marketing solutionsIn this episode, Charlotte describes how the company was built based on feedback from clinical trial teams who struggled with outdated tools like spreadsheets, and emphasizes the importance of technology adoption and collaboration in the clinical trial industry.
Charlotte also shares her experiences and challenges in starting and growing the business, including the decision to raise capital and the need for continuous learning and support.
You can find out more about Charlotte Bradshaw and Evrima here: https://www.linkedin.com/in/charlottebradshaw/ https://www.linkedin.com/company/evrimatechnologies/posts/?feedView=all https://www.evrima.com/
Podcast Takeaways:
Raising awareness about clinical trials is crucial for the advancement of medicine and human health.Evrima aims to make it easier for healthcare providers to access trial information and provide it to their patients.Integrating clinical trial data into existing systems can help identify eligible patients and streamline the recruitment process.The ultimate goal is to have a measurable impact on the clinical trial value chain and ensure that treatments reach the people who need them.The clinical trial industry needs to adopt and embrace technology to overcome challenges and improve processes.Starting and growing a business requires making pivotal decisions, learning quickly, and seeking support from mentors and advisors.Entrepreneurs in the clinical trial space should prioritize mental health and self-care and build a strong network for guidance and support.Chapters
00:00 Introduction and Background
06:11 Identifying the Pain Points in Clinical Research
09:31 The Traditional Approach to Finding Patients for Clinical Trials
11:48 Integrating Clinical Trial Information into Healthcare Practice
15:24 Measuring the Impact of Clinical Trial Solutions
21:36 Raising Awareness and Reducing Taboos
24:22 The Vision and Impact of Evrema
29:01 Challenges and Decisions in Starting and Growing a Business
32:13 Prioritizing Progress over Perfection
36:30 Raising Capital and Building a Support Network
43:30 Expanding the Reach of Evrima and the Future of Clinical Trials
46:28 Lessons Learned and Advice for Budding Entrepreneurs
Keywords:
clinical trials, awareness, patients, doctors, Evrema, barriers, participation, healthcare providers, integration, digital phenotype, impact, Evrima, EveryPath, EveryLink, referral network, recruitment platform, clinical trials, technology adoption, collaboration, starting a business, raising capital, challenges, continuous learning, support
Subscribe for free on Spotify - https://open.spotify.com/show/3Vet6Hn8XFMhprr2LrY3XS G
et in touch in the comments below or head to: https://www.instagram.com/_good_clinical/
Developing Technology to Streamline Clinical Trial Recruitment | Charlotte Bradshaw | Ep 26 -
Today’s guest is John Robson (JR), General Manager at Bridgewest Ventures NZ, and Managing Director of BioOra, a company that is automating the manufacture of CAR T-cells.
This episode is brought to you by SAPRO Consulting: https://www.saproconsulting.com.au/
The development of new technologies, whether it be medical or otherwise, requires a lot of resources. One of those resources is capital - financial capital. Financial capital for new ventures can come in many forms, including loans from Mom & Pop or the bank, angel investment, grants, or private capital.
One of the forms of private capital is venture capital, or VC. VC is characterised by investment in young companies with growth potential. But it's not just about the money. As JR puts it, no founder has every said they were successful because they had an endless supply of money...
In this episode, and I discuss:
The idiosyncrasies of the New Zealand start-up ecosystemVenture Capital's role to play in the ecosystemBridgwest's portfolio of companies working in the CAR space....and much much more.
You can find out more about John Robson and Bridgewest Ventures here:
LinkedIn - John Robson (JR)
LinkedIn - Bridgewest Ventures
https://bridgewest.ventures/
https://bioora.com/
Timestamps:
00:00 Teaser
00:30 Introduction
02:20 True Venture Capital vs. Vulture Capital
05:00 Early Stage / Deep Tech Investment
09:20 Improving the status quo - Infrastructure, Human Capital, Regulation
16:00 Money follows success
20:33 Shaping the world around you
23:15 Doing more with less
25:20 It's not just about the money
26:10 Celebrating, and advertising, our successes
29:45 Where does the money come from - Bridgewest edition
34:30 Industry average is one in ten companies
36:20 Early VC - TechTransfer Office involvement
40:00 Founder Equity - Bespoke arrangements
44:00 Bridgewest's CAR portfolio companies
53:15 Advice for Biotech entrepreneurs
To get in touch head to: https://www.instagram.com/_good_clinical/
Vulture Capital vs. True Venture Capital | John Robson | Ep 25
#goodclinical #goodclinicalpodcast #goodclinicalexplains #goodclinicalevents #goodclinicalnetwork #innovation #podcast #newzealand #commercialization #venturecapital #vc #clinicalresearchassociate #technologytransfer #biotech #science #choices #country #entrepreneur #products #clinicalresearch #biotech #clinicalpractice #chatgcp #healthcare #clinicaltrials #medicine #humanhealth -
Today’s guest is Cameron Quilter, and Clinical Research Associate (CRA) at Novotech.
This episode is brought to you by SAPRO Consulting: https://www.saproconsulting.com.au/
In most Clinical Research Trials, there are three players:
The "Sponsor" - the entity that is funding the research and could be a pharmaceutical company, insitute or other non-profit entity;The "Site" - hospital or private research clinical that is carrying out the research and administering the treatments and other procedures to the patients, andThe "Contract Research Organization", or CRO, which is delegated various responsibilities on behlaf of the sponsor.The Clinical Research Associate, or CRA, is the workhorse of the Sponsor or CRO. CRAs work with staff at the "site" to ensure that the research is conducted according to local and international regulatory and Ethical requirements, and helping to ensure that safety, rights and well-being of research participants are the priority.
CRAs need to have keen attention to detail, a solid understanding of human biology and pharmaceutical science, and an ability to work well with all different personality types and manage the multitude of different "stakeholders". Oh, and being comfortable travelling to different cities every other day is a plus too!
Despite this, the hardest part about a CRA role? Can often be getting a role in the first place! Yet once one has their foot in the door, the CRA role provides a spring-board to take your Science Career in a multitude of different directions.
In this episode, Cameron and I discuss:
How to get land a Clinical Research Associate (CRA) jobThe different careers paths that one can take after a CRA careerSome thoughts on the future of Clinical Research and biotechnology in New Zealand and AustraliaYou can find out more about Cameron and Novotech here:
LinkedIn - Cameron Quilter
LinkedIn - Novotech
Cameron Quilter | How to get a CRA job and how to make the most of it | Ep 24
#goodclinical #goodclinicalpodcast #goodclinicalexplains #goodclinicalevents #goodclinicalnetwork #innovation #podcast #newzealand #commercialization #clinicalresearchassociate #technologytransfer #biotech #science #choices #country #entrepreneur #products #clinicalresearch #biotech #clinicalpractice #chatgcp #healthcare #clinicaltrials #medicine #humanhealth -
Today’s guest is Dr Zahra Champion, Executive Director of BiotechNZ.
This episode is brought to you by SAPRO Consulting: https://www.saproconsulting.com.au/
Biotechnology is a broad category, and ranges from the use of yeast to brew beer, something humans have been doing for the past 9,000 years to manipulating our DNA to fight cancer, something we have been doing for last 20 years. Biotech is a platform technology that sits across all sectors - animal health, agriculture, human health etc.
Modern Biotechnology has the potential to change lives and economies. New Zealand is at a crossroads, after years of onerous regulations stifling advancement in this area, the new government have made moves to re-vamp these regulations to unlock capacity.
But to make a modern biotechnology industry happen, you don't just need benign regulations, you also need smart and motivated individuals and even smarter money. I
n this episode, Dr Champion and I discuss:
What is Biotechnology and where the opportunities areWhat we can learn from other countries that have developed frameworks to support the implementation of biotechnologyAdvice for budding and future biotech entrepreneursYou can find out more about Dr Champion and BiotechNZ here:
LinkedIn - Zahra Champion
BioTECH NZ
Timestamps:
00:00 Teaser
00:30 Introduction
02:50 Regulatory framework holding Biotech back
04:10 Negative implications of not having a Biotech industry
05:30 What is Biotech
08:50 Taking gene technologies from the lab to trial
13:19 Medicinal cannabis: a case study
14:00 New Zealand can adopt the gold-standard of regulations from the world
15:15 Opportunity-cost of NOT having a thriving biotechnology industry
18:20 Biotechnology is expensive
21:00 Early-stage funding is available, but late-stage is not
25:00 Developing a New Zealand flavour for biotech
29:00 Australia vs. New Zealand
31:15 Tall poppy syndrome & showing the world that we are open for business
33:40 Short vs. Long-termism
37:20 Aroa Biosurgery & Neuren Pharmaceuticals set an example
38:50 Smart money = not repeating the same pitfalls
40:30 Internal monologue or dialogue
44:50 Advice for Biotech Entrepreneurs
Dr Zahra Champion | The Future of Biotechnology in New Zealand Ep 23 | Ep23
#goodclinical #goodclinicalpodcast #goodclinicalexplains #goodclinicalevents #goodclinicalnetwork #innovation #podcast #newzealand #commercialization #clinicalresearchassociate #technologytransfer #biotech #science #choices #country #entrepreneur #products #clinicalresearch #biotech #chatgcp #healthcare #clinicaltrials #goodclinical #goodclinicalnetwork #goodclinicalmedia -
Today’s guest is Dr Paul Hamilton, Clinical Director of Early Phase Research at Pacific Clinical Research Network (PCRN).
This episode is brought to you by SAPRO Consulting: https://www.saproconsulting.com.au/
New medicines are first studied in animals before they are tested in humans. Animal testing provides an insight into the efficacy, safety and tolerability of the new medicine. But before a new medicine can be tested on their intended patient population, the so-called "First In Human" (FIH) testing needs to take place. This is typically done in Normal Healthy Volunteers (NHVs) - i.e., a group of healthy individuals, not taking any prescription medications. Once the safety and tolerability of a new medicine has been substantiated in NHVs, only then can the medicine be tested in a patient.
These types of trials are Phase 1 and 1b/2a trials, respectively, and are collectively called "Early Phase Trials". Early Phase trials are an exciting part of the clinical trials spectrum, as this is where the "Proof of Concept" is first determined. And, as Dr Paul Hamilton explains, can deliver impressive health improvements if the technology works as expected.
As time progresses, new medicines become more targeted as we enter the era of "precision medicine". The drugs of tomorrow, are being tested today. The argument for participating in a clinical trial as a patient with a disease is compelling as Dr Hamilton explains in this podcast.
In this episode, Dr Hamilton and I discuss:
The importance of Early Phase Clinical TrialsWhy clinical trials need to be seen as a component of a patient's overall healthcare journey Future opportunities and challenges in the Clinical Research/Trials space in New ZealandYou can find out more about Dr Hamilton and Pacific Clinical Research Network (PCRN) here:
Pacific Clinical Research Network
Paul Hamilton - LinkedIn
PCRN - LinkedIn
Timestamps:
00:00 Teaser
00:22 Introduction
01:30 Pivoting from from medicine and clinical research
08:40 Paul's defining moment in clinical trials - Sofosbuvir
12:30 Danicopan
15:50 The future of medicine starts with Early Phase research
21:30 Early Phase vs. Late Phase
23:30 Setting up a new Early Phase research location
29:25 Clinical trials have a responsibility for delivering healthcare
33:00 Designing good early phase studies
37:00 The Future of Clinical Trials in New Zealand
44:25 Advice for getting into clinical research
Dr Paul Hamilton | Clinical Trials are driving the Future of Medicine and Healthcare | Ep 22
innovation #podcast #newzealand #commercialization #clinicalresearchassociate #technologytransfer #biotech #science #choices #country #entrepreneur #products #clinicalresearch #biotech #clinicalpractice #chatgcp #healthcare #clinicaltrials -
Today’s guest is Dr Brian Ward, Founder and CEO of Aroa Biosurgery, an ASX-listed, biotech company with with a ~$200 m AUD market capitalization.
This episode is brought to you by SAPRO Consulting.
Aroa Biosurgery is a New Zealand-based, ASX-listed biotech company that develops and commercializes novel products that promote wound healing and soft-tissue repair. Their proprietary products, developed from tissue taken from the fore-stomach of sheep, provide the body with structural and biological components that provide a head start in the healing process.
Biotech is a hard business. It's expensive, time-consuming and the road to success is fraught with difficulty and complexity and many biotech companies never make it to profitability. Despite this, there are a number of biotech entrepreneurs with such a fire within them that the odds seem to be in their favour.
Dr Ward's and the Aroa Biosurgery story is remarkable. From the idea, to the product, the manufacturing and commercialzation, the various challenges that have arisen have been overcome resulting in a compelling success story that would inspire any current, or aspiring, biotech entrepreneur.
In this episode, Dr Ward and I discuss:
1. The eureka moment that made Brian pivot from clinical practice to entrepreneurial endeavour
2. The science and technology that underpins their novel products
3. Brian's tips for aspiring biotech entrepreneurs - just get started, understand it will not be easy, be prepared for a "game of attrition" and surround your self with people smarter than you.
You can find out more about Brian Ward and Aroabiosurgery here:
LinkedIn - Dr Brian Ward
LinkedIn - Aroa Biosurgery
Aroa Biosurgery Website -
Today’s guest is Madhu Vyas, Theranostics Site Leader at Mercy Radiology, and Programme Lead at Unitec.
This episode is brought to you by SAPRO Consulting PTY Ltd https://www.saproconsulting.com.au/
Nuclear Medicine, Molecular Imaging and Radiochemistry sound like terms pulled straight from a science fiction novel. Yet the use of radioactive materials for the purposes of diagnosing and treating disease - collectively referred to as theranostics (therapy + diagnostics) - are commonly place and an exciting field of discovery and development.
But with so many different radioactive materials to choose from, each with their own characteristics, how do researchers and physicians choose the right one? And how is the radiation targeted to the desired organ or diseased tissue without damaging normal tissue?
In this episode, Madhu and I discuss:
1. The origins of nuclear medicine, molecular imaging and "theranostics"
2. How radioactive material is targeted to different tissues within a patient for the purposes of either diagnosis or therapy
3. What we can expect for the future of an area of medicine that is now hitting it's stride
Madhu Vyas' passion for this field is palpable. When not working as the Theranostics Site Leader at Mercy Radiology, he is teaching the next generation of Medical Imaging technicians and also completing a PhD. Clearly, Madhu has discovered a way to wring more than 24 hours out of a single day!
You can find out more about Madhu, Mercy Radiology & Unitec:
https://www.linkedin.com/in/150880/
https://www.linkedin.com/company/mercy-radiology/ https://radiology.co.nz/ https://www.linkedin.com/school/unitecnz/
https://www.unitec.ac.nz/
#newzealand #radiochemistry #radiation #radiationtherapy #theranostics #nuclear #nuclearimaging #molecularimaging #theranos #innovation #podcast #commercialization #science #entrepreneurship #innovation - Visa fler
